IL-17 targeted therapies for psoriasis.

Psoriasis is a chronic, disabling, inflammatory skin disease whose pathogenesis still remains to be fully elucidated. Genetic and environmental factors induce an immune response mediated by several cytokines and chemokines, including IL-17A.
Emerging evidence now suggests that IL-17A is central in the pathogenesis of psoriasis. Three agents neutralizing IL-17 (i.e., secukinumab and ixekizumab) or antagonizing its receptor (i.e., brodalumab) are in development and are being studied in Phase III clinical trials to evaluate their overall efficacy and safety. However, Phase II results of IL-17 blockade with each of these agents has shown a marked improvement of disease severity, thus confirming the pathogenic relevance of IL-17 in mediating crucial inflammatory circuits in psoriasis.
Anti-IL-17 agents are likely to become important future therapeutics in this disease and the may potentially impact on cardiovascular diseases, arthritis and other comorbidities associated with psoriasis.
AuthorsAndrea Chiricozzi, James G Krueger
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 22 Issue 8 Pg. 993-1005 (Aug 2013) ISSN: 1744-7658 [Electronic] England
PMID23731078 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Biological Factors
  • Interleukin-17
  • Antibodies, Monoclonal (therapeutic use)
  • Biological Factors (therapeutic use)
  • Humans
  • Interleukin-17 (antagonists & inhibitors, immunology)
  • Psoriasis (drug therapy, genetics, immunology)
  • Transcriptome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: